- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07632963
Addressing HPV Vaccine Hesitancy by Co-Designing a Digital Health Intervention (HPV-END-IT)
HPV-Kompassen: a Mixed-Methods Single-Arm Cluster Feasibility Study of a Co-Designed Web-Based Intervention To Strengthen HPV Vaccine Confidence and Uptake in Stockholm, Sweden
This study looks at a digital platform that supports HPV vaccination in schools. The goal is to see if it is useful, easy to use, and practical in real school settings, especially in areas where fewer people get vaccinated.
Researchers will give Year 5 pupils (aged 11-12) and their parents or caregivers access to the platform. It provides clear, trusted information about the HPV vaccine for young people, parents, and school nurses. The aim is to make the vaccine easier to understand and to help answer any questions or concerns.
After using the platform, participants will be asked to share their thoughts.
연구 개요
연구 유형
등록 (추정된)
단계
- 해당 없음
연락처 및 위치
연구 연락처
- 이름: Helena Avermark
- 전화번호: +4670-890 25 04
- 이메일: helena.avermark@ki.se
연구 연락처 백업
- 이름: Asha Mohamed Ibrahim
- 이메일: asha.mohamed.ibrahim@ki.se
참여기준
자격 기준
공부할 수 있는 나이
- 어린이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
We will aim to recruit 6-8 compulsory schools in Stockholm County to serve as clusters.
All Year 5 pupils and their caregivers in the study schools are invited.
Inclusion Criteria:
- The school provides education to pupils in school year 5 and is scheduled to be open throughout the pilot trial period
- The school is located in an area with HPV vaccine uptake <85.2% (the Stockholm regional average)
- The head principal and school nurse both consent to participate
- The school has the capacity to implement the intervention
Exclusion Criteria:
- Failure to meet the inclusion criteria
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Intervention arm
Participants in the intervention arm receive access to the co-designed, digital platform HPV-Kompassen (eng: The HPV Compass).
|
HPV-Kompassen is a co-designed, web-based platform that provides tailored and synthesised information with the aim of strengthening confidence in and uptake of the HPV vaccine.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Feasibility of implementation: Acceptability, appropriateness and feasibility of implementation
기간: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Measured using Weiner et al.'s implementation outcomes questionnaire (administered to school nurses in participating schools). The questionnaire consists of 12 statements, with four items each assessing the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), and the Feasibility of Intervention Measure (FIM). Respondents rate their level of agreement with each statement using a five-point Likert scale, ranging from "completely disagree" to "completely agree." Responses are coded numerically from 1 to 5, with higher scores indicating stronger agreement. The 12 scores are summed to produce a total scale score ranging from 12 to 60, with higher scores reflecting more positive perceptions of the platform across the three implementation domains. |
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
|
Feasibility of implementation: Acceptability, appropriateness and feasibility of implementation
기간: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Qualitative data will be collected through semi-structured interviews with school nurses in participating schools.
An interview guide developed guided by the Consolidated Framework for Implementation Research (CFIR) will be used to ensure consistency while allowing flexibility to explore individual experiences in depth.
The guide includes open-ended questions designed to capture perceptions (see outcome measure 5) and questions related to implementation, e.g., 'How did you experience implementing HPV-Kompassen alongside the regular school health services program?' and 'How well did HPV-Kompassen fit with how schools provide information about HPV vaccination?'.
|
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
|
Acceptability of intervention: Intervention delivery strategy
기간: Throughout the intervention period (i.e., months 0-7).
|
Defined as proportion of adolescents and caregivers that access platform at least once, measured through platform usage metrics.
|
Throughout the intervention period (i.e., months 0-7).
|
|
Acceptability of intervention: Usability of intervention
기간: Immediately after the intervention period (i.e., 'end of treatment') at 7 months.
|
Usability is measured quantitatively using the Swedish version of the System Usability Scale (SUS).
The SUS consists of 10 items assessing perceived usability across key dimensions such as complexity, ease of use, and confidence in using the system.
Participants (school nurses, adolescents and caregivers) indicate their agreement with each item on a five-point Likert scale ranging from "strongly disagree" to "strongly agree."
Responses are scored according to standard SUS procedures, resulting in a total score ranging from 0 to 100, with higher scores indicating better perceived usability.
|
Immediately after the intervention period (i.e., 'end of treatment') at 7 months.
|
|
Acceptability of intervention: Perceptions of intervention
기간: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Qualitative data will be collected through semi-structured interviews with participants (school nurses, adolescents and caregivers), focusing on their perceptions of the intervention.
An interview guide is used to ensure coverage of key domains while allowing flexibility to explore individual experiences in depth.
The guide includes open-ended questions assessing implementation (see outcome measure 2) and perceptions of the intervention, such as "Can you briefly describe your experience of using HPV-Kompassen?" and "Did the information seem credible to you?".
|
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
|
Acceptability of intervention: Intervention engagement
기간: Throughout the intervention period (i.e., months 0-7).
|
Defined as proportion of adolescents and caregivers that actively engage with the platform least once (e.g., visit different modules), measured through platform usage metrics.
|
Throughout the intervention period (i.e., months 0-7).
|
|
Acceptability of intervention: Intervention engagement
기간: End of intervention period (i.e., 'end of treatment') at 7 months.
|
Qualitative data collection using semi-structured interviews.
These interviews aim to understand how, why, and to what extent participants engaged with the platform in practice.
Participants (school nurses, adolescents and caregivers) are asked open-ended questions such as "Why did you choose to use the platform?"
and "Why did you not use the platform, or use it less than expected?"
Additional questions explore when and how the platform was accessed, which features were used, and what factors influenced engagement (e.g., time constraints, relevance of content, or integration with existing workflows).
|
End of intervention period (i.e., 'end of treatment') at 7 months.
|
|
Feasibility of trial protocol: Feasibility of recruitment
기간: From start of school enrollment (i.e., pre-intervention) and throughout the intervention period (i.e., months 0-7).
|
Measured through study notes, assessing two indicators: proportion of schools that consent to participate and proportion of participants that consent to participate in interviews.
|
From start of school enrollment (i.e., pre-intervention) and throughout the intervention period (i.e., months 0-7).
|
|
Feasibility of trial protocol: Participant retention
기간: From school enrollment (i.e., 'baseline') and throughout the intervention period (i.e., months 0-7).
|
Measured using study records and platform metrics, assessing two indicators: Proportion of schools retained until study end and proportion of participants using platform who complete the end line survey.
|
From school enrollment (i.e., 'baseline') and throughout the intervention period (i.e., months 0-7).
|
|
Feasibility of trial protocol: Feasibility of data collection methods
기간: Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
Measured using study records and survey data, assessing the completeness of data.
|
Shortly after the intervention period (i.e., 'end of treatment') at 7 months.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Sibylle Herzig van Wees, Associate Professor, Karolinska Institutet
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
HPV에 대한 임상 시험
-
Xiamen UniversityXiamen Innovax Biotech Co., Ltd; Xiamen Center for Disease Control and Prevention아직 모집하지 않음HPV 예방접종률 | HPV 백신 인식 | HPV 백신 접종 의도
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)완전한
-
Xiamen UniversityXiamen Center for Disease Control and Prevention아직 모집하지 않음HPV 예방접종률 | HPV 백신 인식 | HPV 백신 접종 의도
-
Population Services InternationalFederal Democratic Republic of Ethiopia Ministry of Health; Addis Ababa University, College...아직 모집하지 않음청소년 건강 | HPV 백신 허용 가능성 | HPV 백신 | 통합 커뮤니티 기반 개입 패키지 | 유두종 바이러스 백신 | HPV 백신에 대한 태도 | 청소년 건강 서비스 | HPV 예방접종 | HPV 백신 지식
-
University of PennsylvaniaWorld Bank Group아직 모집하지 않음HPV 백신 | HPV
-
Global Alliance to Immunize Against AIDS Vaccine...Merck Sharp & Dohme LLC완전한HPV 관련 자궁경부암 | HPV
-
Indiana UniversityMerck Sharp & Dohme LLC완전한
-
Centre Hospitalier Universitaire de la Réunion모병
HPV-Kompassen에 대한 임상 시험
-
Zhejiang Provincial Center for Disease Control...모집하지 않고 적극적으로흥역 | 풍진 | 유행성 이하선염 | 인간 유두종 바이러스 감염 유형 16 | 인간 유두종 바이러스 감염 유형 18중국
-
Instituto Nacional de Cancerologia, Columbia모집하지 않고 적극적으로
-
University of California, Los AngelesNational Cancer Institute (NCI); American Medical Group Association모병
-
Xiamen UniversityXiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.완전한
-
H. Lee Moffitt Cancer Center and Research InstituteFlorida Department of Health; Health Choice Network정지된
-
Emel GÜÇLÜ CİHANKahramanmaras Sutcu Imam University모병
-
University of AarhusNeighbourhood mothers, Gellerup; Aarhus Municipality, Denmark완전한